Page last updated: 2024-10-27

gemfibrozil and Glycogen Storage Disease Type I

gemfibrozil has been researched along with Glycogen Storage Disease Type I in 1 studies

Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.

Research Excerpts

ExcerptRelevanceReference
"Because the complications of hyperlipidemia are caused mainly by TC, thereby, by maintaining it at a normal level, we could set a TG target by the linear equation that allowed a certain degree of hypertriglyceridemia."1.56Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I. ( Hong, YH; Ma, MS; Qiu, ZQ; Sun, ZX; Wei, M; Xu, YW; Yuan, YH; Zhang, ZJ, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhang, ZJ1
Yuan, YH1
Ma, MS1
Hong, YH1
Sun, ZX1
Xu, YW1
Wei, M1
Qiu, ZQ1

Other Studies

1 other study available for gemfibrozil and Glycogen Storage Disease Type I

ArticleYear
Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:19

    Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Fenofibrate; Gemfibrozil; Glucose-6

2020